ANI Pharmaceuticals | ANIP - Selling And Administration Expenses


ANI Pharmaceuticals reported $73.66M in Selling and Administration Expenses for its fiscal quarter ending in March of 2026.





Selling And Administration Expenses Change Date
AbbVie USD 3.63B 54M Jun/2026
ANI Pharmaceuticals USD 73.66M 9.14M Mar/2026
Aurora Cannabis CAD 41.4M 781K Mar/2026
Canopy Growth CAD 31.17M 2.27M Mar/2026
Eli Lilly USD 2.93B 198M Mar/2026
Emergent BioSolutions USD 182.8M 82.3M Jun/2023
Heron Therapeutics USD 23.74M 605K Dec/2025
Hikma Pharmaceutical USD 288M 149M Dec/2025
Knight Therapeutics CAD 35.45M 4.43M Dec/2025
Nektar Therapeutics USD 11.87M 1.7M Mar/2026
Novartis USD 3.14B 296M Mar/2026
Omeros USD 11.32M 2.48M Sep/2024
Perrigo USD 267.3M 11.4M Mar/2026
Sun Pharmaceuticals INR 24.89B 637.6M Mar/2025
Teva Pharmaceutical Industries USD 1.03B 34M Jun/2026